Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.

Szijgyarto Z, Flach KD, Opdam M, Palmieri C, Linn SC, Wesseling J, Ali S, Bliss JM, Cheang MCU, Zwart W, Coombes RC.

Breast Cancer Res Treat. 2019 May;175(1):149-163. doi: 10.1007/s10549-018-05110-x. Epub 2019 Jan 24.

2.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, Boileau JF, Provencher L, Robidoux A, Rimawi M, McIntosh SA, Shalaby I, Stein RC, Thirlwell M, Dolling D, Morden J, Snowdon C, Perry S, Cornman C, Batten LM, Jeffs LK, Dodson A, Martins V, Modi A, Osborne CK, Pogue-Geile KL, Cheang MCU, Wolmark N, Julian TB, Fisher K, MacKenzie M, Wilcox M, Huang Bartlett C, Koehler M, Dowsett M, Bliss JM, Jacobs SA.

J Clin Oncol. 2019 Jan 20;37(3):178-189. doi: 10.1200/JCO.18.01624. Epub 2018 Dec 6.

PMID:
30523750
3.

A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics.

Quist J, Mirza H, Cheang MCU, Telli ML, O'Shaughnessy JA, Lord CJ, Tutt ANJ, Grigoriadis A.

Mol Cancer Ther. 2019 Jan;18(1):204-212. doi: 10.1158/1535-7163.MCT-18-0243. Epub 2018 Oct 10.

4.

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.

Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K, Sestak I, Gao Q, Cuzick J, Dowsett M.

Breast Cancer Res. 2018 Sep 4;20(1):103. doi: 10.1186/s13058-018-1040-9.

5.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.

Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.

6.

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.

Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A, Lønning PE, Morden J, Porta N, Jassem J, van De Velde CJ, Rasmussen BB, Verhoeven D, Bartlett JMS, Coombes RC; PathIES Sub-Committee.

Breast Cancer Res Treat. 2018 Feb;168(1):169-178. doi: 10.1007/s10549-017-4543-7. Epub 2017 Nov 24.

7.

Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials.

Laurberg T, Tramm T, Nielsen T, Alsner J, Nord S, Myhre S, Sørlie T, Leung S, Fan C, Perou C, Gelmon K, Overgaard J, Voduc D, Prat A, Cheang MCU.

Acta Oncol. 2018 Jan;57(1):38-43. doi: 10.1080/0284186X.2017.1401735. Epub 2017 Nov 25.

PMID:
29172851
8.

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MCU, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788b. No abstract available.

PMID:
28586336
9.

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2017 Apr 7;23(4):526. doi: 10.1038/nm0417-526c. No abstract available.

PMID:
28388604
10.

PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2016 Nov;22(11):1303-1313. doi: 10.1038/nm.4198. Epub 2016 Oct 24. Erratum in: Nat Med. 2017 Apr 7;23 (4):526. Nat Med. 2017 Jun 6;23 (6):788.

11.

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.

Perez EA, Ballman KV, Mashadi-Hossein A, Tenner KS, Kachergus JM, Norton N, Necela BM, Carr JM, Ferree S, Perou CM, Baehner F, Cheang MC, Thompson EA.

J Natl Cancer Inst. 2016 Oct 28;109(2). pii: djw207. Print 2017 Feb.

12.

αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis.

Voduc KD, Nielsen TO, Perou CM, Harrell JC, Fan C, Kennecke H, Minn AJ, Cryns VL, Cheang MCU.

NPJ Breast Cancer. 2015 Oct 21;1. pii: 15014. doi: 10.1038/npjbcancer.2015.14.

13.

Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.

Prat A, Cheang MC, Galván P, Nuciforo P, Paré L, Adamo B, Muñoz M, Viladot M, Press MF, Gagnon R, Ellis C, Johnston S.

JAMA Oncol. 2016 Oct 1;2(10):1287-1294. doi: 10.1001/jamaoncol.2016.0922.

PMID:
27281556
14.

Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.

Klintman M, Buus R, Cheang MC, Sheri A, Smith IE, Dowsett M.

Clin Cancer Res. 2016 May 15;22(10):2405-16. doi: 10.1158/1078-0432.CCR-15-1488.

15.

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.

López-Knowles E, Gao Q, Cheang MC, Morden J, Parker J, Martin LA, Pinhel I, McNeill F, Hills M, Detre S, Afentakis M, Zabaglo L, Dodson A, Skene A, Holcombe C, Robertson J, Smith I, Bliss JM, Dowsett M; POETIC trialists.

Breast Cancer Res. 2016 Apr 1;18(1):39. doi: 10.1186/s13058-016-0696-2.

16.

Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).

Barry GS, Cheang MC, Chang HL, Kennecke HF.

Oncotarget. 2016 Apr 5;7(14):18953-64. doi: 10.18632/oncotarget.8006.

17.

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.

Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, Viladot M, Pineda E, Arance A, Muñoz M, Paré L, Cheang MC, Adamo B, Perou CM.

BMC Med. 2015 Dec 18;13:303. doi: 10.1186/s12916-015-0540-z.

18.

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA.

J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2.

19.

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA.

Oncologist. 2015 May;20(5):474-82. doi: 10.1634/theoncologist.2014-0372. Epub 2015 Apr 23.

20.

Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.

Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, Gillett C, Pinder S, Vanoli F, Jasin M, Mayrhofer M, Isaksson A, Cheang MC, Mirza H, Frankum J, Lord CJ, Ashworth A, Vinayak S, Ford JM, Telli ML, Grigoriadis A, Tutt AN.

Cancer Discov. 2015 May;5(5):488-505. doi: 10.1158/2159-8290.CD-14-1092. Epub 2015 Mar 13.

21.

Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER.

Sun Z, Prat A, Cheang MC, Gelber RD, Perou CM.

Ann Oncol. 2015 Jan;26(1):70-4. doi: 10.1093/annonc/mdu493. Epub 2014 Oct 29.

PMID:
25355719
22.

Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E.

Br J Cancer. 2014 Oct 14;111(8):1532-41. doi: 10.1038/bjc.2014.444. Epub 2014 Aug 7.

23.

Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients.

Oh DS, Cheang MC, Fan C, Perou CM.

Radiat Res. 2014 Feb;181(2):193-207. doi: 10.1667/RR13485.1. Epub 2014 Feb 14.

24.

Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.

Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez F, Gianni L, Baselga J.

Clin Cancer Res. 2014 Jan 15;20(2):511-21. doi: 10.1158/1078-0432.CCR-13-0239.

25.

Predicting drug responsiveness in human cancers using genetically engineered mice.

Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, Prat A, Cheang MC, Herschkowitz JI, Rosen JM, Zamboni W, Sharpless NE, Perou CM.

Clin Cancer Res. 2013 Sep 1;19(17):4889-99. doi: 10.1158/1078-0432.CCR-13-0522. Epub 2013 Jun 18.

26.

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.

Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM.

Oncologist. 2013;18(2):123-33. doi: 10.1634/theoncologist.2012-0397. Epub 2013 Feb 12. Review.

27.

Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.

Prat A, Cheang MC, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM.

J Clin Oncol. 2013 Jan 10;31(2):203-9. doi: 10.1200/JCO.2012.43.4134. Epub 2012 Dec 10.

28.

Use of mutation profiles to refine the classification of endometrial carcinomas.

McConechy MK, Ding J, Cheang MC, Wiegand K, Senz J, Tone A, Yang W, Prentice L, Tse K, Zeng T, McDonald H, Schmidt AP, Mutch DG, McAlpine JN, Hirst M, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG.

J Pathol. 2012 Sep;228(1):20-30. doi: 10.1002/path.4056. Epub 2012 Jul 18.

29.

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM.

Ann Oncol. 2012 Nov;23(11):2866-73. doi: 10.1093/annonc/mds080. Epub 2012 Apr 24.

30.

Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.

Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO.

Clin Cancer Res. 2012 Apr 15;18(8):2402-12. doi: 10.1158/1078-0432.CCR-11-2956. Epub 2012 Feb 20.

31.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25.

32.

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.

Martin M, Romero A, Cheang MC, López García-Asenjo JA, García-Saenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Caldés T, Vidart JA, Lopez-Tarruella S, Diaz-Rubio E, Perou CM.

Breast Cancer Res Treat. 2011 Jul;128(1):127-36. doi: 10.1007/s10549-011-1461-y. Epub 2011 Apr 5.

PMID:
21465170
33.

Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T.

Am J Pathol. 2011 Apr;178(4):1453-60. doi: 10.1016/j.ajpath.2010.12.042. Review.

34.

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.

Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ.

Clin Cancer Res. 2010 Nov 1;16(21):5222-32. doi: 10.1158/1078-0432.CCR-10-1282. Epub 2010 Sep 13.

35.

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.

Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D.

PLoS Med. 2010 May 25;7(5):e1000279. doi: 10.1371/journal.pmed.1000279.

36.

Metastatic behavior of breast cancer subtypes.

Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K.

J Clin Oncol. 2010 Jul 10;28(20):3271-7. doi: 10.1200/JCO.2009.25.9820. Epub 2010 May 24.

PMID:
20498394
37.

Breast cancer subtypes and the risk of local and regional relapse.

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H.

J Clin Oncol. 2010 Apr 1;28(10):1684-91. doi: 10.1200/JCO.2009.24.9284. Epub 2010 Mar 1.

PMID:
20194857
38.

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. doi: 10.1093/jnci/djp082. Epub 2009 May 12.

39.

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.

Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, Nielsen TO.

Breast Cancer Res Treat. 2010 Jan;119(1):53-61. doi: 10.1007/s10549-009-0318-0. Epub 2009 Feb 10.

PMID:
19205877
40.

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C.

J Clin Oncol. 2009 Mar 10;27(8):1168-76. doi: 10.1200/JCO.2008.18.1024. Epub 2009 Feb 9.

41.

Supervised risk predictor of breast cancer based on intrinsic subtypes.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS.

J Clin Oncol. 2009 Mar 10;27(8):1160-7. doi: 10.1200/JCO.2008.18.1370. Epub 2009 Feb 9.

42.

Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer.

So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M.

Clin Cancer Res. 2008 Nov 1;14(21):6944-54. doi: 10.1158/1078-0432.CCR-08-0408.

43.

Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.

Crabb SJ, Cheang MC, Leung S, Immonen T, Nielsen TO, Huntsman DD, Bajdik CD, Chia SK.

Clin Breast Cancer. 2008 Jun;8(3):249-56. doi: 10.3816/CBC.2008.n.028.

PMID:
18650155
44.

The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.

Voduc D, Nielsen TO, Cheang MC, Foulkes WD.

Hum Pathol. 2008 Oct;39(10):1431-7. doi: 10.1016/j.humpath.2008.03.004. Epub 2008 Jul 11.

PMID:
18620730
45.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

46.

Gene expression profiling of breast cancer.

Cheang MC, van de Rijn M, Nielsen TO.

Annu Rev Pathol. 2008;3:67-97. Review.

PMID:
18039137
47.

Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases.

Turbin DA, Leung S, Cheang MC, Kennecke HA, Montgomery KD, McKinney S, Treaba DO, Boyd N, Goldstein LC, Badve S, Gown AM, van de Rijn M, Nielsen TO, Gilks CB, Huntsman DG.

Breast Cancer Res Treat. 2008 Aug;110(3):417-26. Epub 2007 Oct 3.

PMID:
17912629
48.

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.

Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD.

BMC Cancer. 2007 Jul 24;7:134.

49.

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases.

Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG.

Breast Cancer Res Treat. 2008 Jan;107(2):249-57. Epub 2007 Mar 13.

50.

Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.

Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM.

J Clin Oncol. 2006 Dec 20;24(36):5637-44. Epub 2006 Nov 20.

PMID:
17116944

Supplemental Content

Loading ...
Support Center